魯抗醫藥(600789.SH):醋酸鈣顆粒獲藥品註冊批件
格隆匯1月10日丨魯抗醫藥(600789.SH)公佈,近日,公司收到國家藥品監督管理局頒發的關於醋酸鈣顆粒的《藥品註冊批件》(批件號:2019S00714、2019S00715)。
醋酸鈣屬於有機酸鈣,具有溶解性比無機酸鈣好,pH值接近中性,對胃腸刺激較小等方面的優點。用於預防和治療鈣缺乏症,如骨質疏鬆、手足抽搐症、骨發育不全、佝僂病以及兒童、妊娠和哺乳期婦女、絕經期婦女、老年人鈣的補充。
根據中國化學制藥工業協會數據顯示,2019年上半年國內鈣製劑樣本醫院銷售額約為5.18億元人民幣。目前醋酸鈣顆粒國內有昆明邦宇製藥有限公司、河南諾美藥業有限公司獲批生產,本公司為第三家獲批。截止目前,公司在該藥品的研發投入約為174萬元人民幣(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.